How Molecular Docking Supports Drug Repurposing: From Existing-Drug Libraries to Testable Target Hypotheses
Learn how to curate existing-drug libraries, validate a molecular docking protocol, review structural hypotheses, and prioritize candidates for experimental repurposing studies.
Drug repurposing, also called drug repositioning, searches for new therapeutic uses of compounds that already have development or clinical history. That pool can include approved medicines, investigational compounds, and discontinued or shelved candidates whose identities and prior evidence are still accessible. The attraction is not that discovery work disappears. It is that a project can begin with more pharmacological and development knowledge than a completely new chemical series [1].
Structure-based docking is especially relevant when a credible protein target and a usable binding-site model are available. It asks a focused question: which existing compounds deserve attention because their predicted poses are compatible with this site under a declared protocol? This is narrower than predicting a therapeutic effect, and precisely narrow enough to produce an actionable screening decision.
Define what is being repurposed
Candidate pools and the evidence they bring
| Candidate pool | Useful prior knowledge | Question that remains |
|---|---|---|
| Approved medicines | Authorized indication, formulation, dosing history, labeling, and post-market information may be available. | Can the compound engage the new target at an exposure and regimen relevant to the proposed use? |
| Investigational compounds | Preclinical or clinical data may reveal target activity, exposure, tolerability, and reasons for discontinuation. | Does the new rationale overcome the earlier limitation, and are the data and compound accessible? |
| Shelved or discontinued compounds | A defined chemical entity and partial development package may exist. | Was development stopped for a reason that also matters to the new indication? |
| Known bioactive compounds | Published mechanism or assay evidence may connect the molecule to a pathway or target family. | Is the evidence strong enough, and is the molecule truly development-ready? |
The label attached to a library should therefore be precise. An “approved-drug library” is not interchangeable with a broader repurposing collection, and the same active ingredient may appear as different salts, stereoisomers, formulations, or records.
Start from a target and indication question
Minimum evidence before screening
| Starting record | Decision it supports |
|---|---|
| Target rationale | Explains why modulating this protein could matter in the proposed disease context. |
| Direction of modulation | Distinguishes whether inhibition, activation, stabilization, or another mechanism is required. |
| Binding-site rationale | Defines why the selected pocket is connected to the desired mechanism. |
| Receptor state | Records construct, conformation, cofactors, metals, retained waters, protonation assumptions, and structure provenance. |
| Reference ligands or known binders | Provide controls for search-space placement, redocking, enrichment, and pose interpretation. |
| Downstream assay path | Ensures that a prioritized candidate can be tested for the intended target and biological effect. |
This order matters. Docking an entire drug library before defining the biological question can produce an impressive table of scores without a defensible route from prediction to experiment.
Curate the existing-drug library as scientific data
Fields worth preserving for every compound
| Field | Why it matters |
|---|---|
| Stable compound identifier and source | Connects the modeled structure to the correct database or physical sample. |
| Parent compound, salt, and formulation relationship | Prevents a modeled neutral parent from being confused with the marketed material. |
| Stereochemistry, tautomer, and protonation state | Controls the actual three-dimensional and electrostatic species presented to docking. |
| Approval or development status with jurisdiction and date | Avoids treating regulatory status as timeless or globally identical. |
| Known targets, mechanism, and indication | Reveals helpful pharmacology, polypharmacology, and contradictions to the new hypothesis. |
| Exposure, route, dose, and safety evidence | Provides the later feasibility context that a docking result cannot calculate. |
| Prepared structure and transformation log | Makes the exact docked molecular representation traceable. |
Deduplication should happen at both record and chemical levels. Two database entries can describe the same active moiety, while two stereoisomers with similar names can be different modeling and pharmacology problems. Keep the source record even when a prepared docking structure is standardized.
Validate the protocol before ranking the library
A repurposing screen still inherits every ordinary docking decision: receptor choice, pocket definition, molecular preparation, scoring function, search effort, pose count, and comparison rule. Validate those choices using evidence appropriate to the target. The BioChemIntelli guide to validating a molecular docking workflow explains the relevant control logic in detail. Redocking can test whether a known pose is recoverable. Cross-docking can test transfer across receptor structures. Known actives and suitable decoys can test whether the protocol enriches relevant chemistry. Sensitivity analyses can reveal whether a shortlist is stable to plausible preparation or search changes.
AutoDock Vina 1.2 introduced documented scoring and batch capabilities that support library workflows [4]. Those capabilities execute a protocol; they do not decide whether that protocol represents the target state or the intended repurposing question. The validation record should travel with the ranked output.
A practical target-based repurposing workflow
| Step | Action | Output |
|---|---|---|
| 1. Define the hypothesis | State the disease context, target, required modulation, binding site, and evidence that would change the decision. | A falsifiable target-indication question. |
| 2. Curate the library | Resolve identities, statuses, structures, duplicates, stereochemistry, and known pharmacology. | A traceable existing-drug collection. |
| 3. Prepare the receptor and ligands | Declare structural states and apply consistent transformations while preserving provenance. | Reviewable docking inputs. |
| 4. Validate the protocol | Use reference poses, known ligands, decoys, or alternative structures as the available evidence permits. | A documented domain of interpretation. |
| 5. Run the controlled screen | Hold the declared engine, scoring method, box, search settings, and output policy consistent. | Comparable poses and protocol-dependent scores. |
| 6. Review and annotate | Inspect pose geometry, key interactions, clashes, alternate modes, chemical diversity, and known target conflicts. | A structurally reasoned candidate set. |
| 7. Integrate and test | Combine structural evidence with exposure, safety, pharmacology, assay feasibility, and experimental results. | A prioritized experimental plan and an auditable decision. |
Review every candidate in two evidence layers
Structural evidence and repurposing feasibility
| Layer | Questions | Typical evidence |
|---|---|---|
| Structural hypothesis | Is the pose plausible? Are key interactions and pocket occupancy consistent with the desired mechanism? Are alternate poses or receptor states important? | Docked poses, reference structures, interaction geometry, controlled scores, redocking, cross-docking, and sensitivity checks. |
| Repurposing feasibility | Can relevant target engagement be achieved? Does existing pharmacology support or contradict the idea? Is the compound testable in the required assay and biological context? | Known targets, biochemical and cellular data, route and exposure, dose, safety history, formulation, tissue access, disease evidence, and experimental confirmation. |
The two layers can disagree productively. A compelling pose may be deprioritized because the necessary concentration is not realistic. A moderately ranked compound may advance because known exposure, mechanism, chemical diversity, and assay readiness make it the more informative experiment. Computational repurposing reviews consistently place validation and evidence integration after prediction rather than treating them as optional decoration [1,2]. For the next decision step, see the practical guide to selecting compounds after docking.
Build a shortlist for learning, not a list of winners
A decision matrix for experimental nomination
| Criterion | Useful question | Reason to retain diversity |
|---|---|---|
| Pose plausibility | Does the candidate support the required interaction hypothesis without obvious clashes or strained geometry? | Different credible chemotypes can test whether the pocket model is robust. |
| Protocol stability | Does the candidate remain interpretable across justified receptor or preparation choices? | A fragile top rank may be less useful than several stable hypotheses. |
| Known pharmacology | Do existing targets or mechanisms reinforce, complicate, or contradict the new target hypothesis? | Contrasting pharmacological profiles can clarify observed assay effects. |
| Exposure feasibility | Is there a credible path to concentrations relevant to the planned experiment or disease site? | Several exposure profiles can reveal which constraint controls progression. |
| Assay readiness | Can identity, purity, target engagement, and functional response be measured with suitable controls? | Testable candidates generate evidence sooner than inaccessible theoretical winners. |
| Information gain | What will a positive or negative result teach about the target, pocket, mechanism, or protocol? | A deliberately varied set reduces the risk of learning the same answer repeatedly. |
A published example: docking followed by experimental verification
Wu and colleagues screened drugs from an FDA-focused database against three alpha-glucosidase protein structures using a cross- docking strategy. They selected candidates from predicted binding affinities and modes, then tested activity in vitro. Raloxifene inhibited alpha-glucosidase in that assay, after which the authors used additional simulations and interaction analyses to examine the proposed complexes [3].
The useful lesson is the sequence of evidence. Docking narrowed the candidates and proposed binding modes. An assay supplied a new experimental observation. Additional calculations explored the structural model. The study did not make docking itself equivalent to a treatment decision, and this article does not infer clinical usefulness from that single target-level result.
Where MolNexus fits in a drug-repurposing screen
MolNexus can support the local structure-based screening portion of a target-centric repurposing project. The current Windows desktop application connects visible receptor and ligand preparation review, interaction-box setup, AutoDock Vina 1.2.7 execution with Vina or Vinardo scoring, batch handling, pose inspection, local SQLite job history, and scientific exports. This can help a researcher keep the prepared drug structures, controlled settings, poses, and review records connected while building a shortlist.
MolNexus does not choose the disease indication, establish the target rationale, curate regulatory status, calculate clinically achievable exposure, validate target engagement, or perform biochemical, cellular, animal, or clinical studies. Those remain project decisions and evidence streams outside the docking workspace. The published MolNexus offer is for one Windows PC at a time, and checkout remains closed while the commercial release is completed.
For an individual researcher, the evaluation question is whether a guided local workspace improves preparation review, comparative docking, and record keeping. For a laboratory, it is whether the documented one-PC workflow fits the technical method and evidence handoff; team or institutional licensing is not currently published.
Frequently asked questions
References
- Ziaurrehman Tanoli, Adrià Fernández-Torras, Umut Onur Özcan, et al.. Computational drug repurposing: approaches, evaluation of in silico resources and case studies Nature Reviews Drug Discovery (2025) DOI: 10.1038/s41573-025-01164-x Current review of computational drug-repurposing approaches, resource selection, evidence integration, and practical case studies.
- Malvika Pillai and Di Wu. Validation approaches for computational drug repurposing: a review AMIA Annual Symposium Proceedings (2024) Systematic review of computational, experimental, and clinical validation used in published drug-repurposing studies.
- Jiaofeng Wu, Baichun Hu, Shuaizhong Lu, Rong Duan, Haoran Deng, Lele Li, Lijuan He, Yunli Zhao, Jian Wang, and Zhiguo Yu. Identification of raloxifene as a novel α-glucosidase inhibitor using a systematic drug repurposing approach in combination with cross molecular docking-based virtual screening and experimental verification Carbohydrate Research (2022) DOI: 10.1016/j.carres.2021.108478 Original study connecting cross-docking of an FDA-focused drug collection to in vitro alpha-glucosidase testing and subsequent computational analyses.
- Jerome Eberhardt, Diogo Santos-Martins, Andreas F. Tillack, and Stefano Forli. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings Journal of Chemical Information and Modeling (2021) DOI: 10.1021/acs.jcim.1c00203 Authoritative repository copy documenting the AutoDock Vina 1.2 engine family, scoring methods, and batch capabilities.